Charles River Laboratories International, Inc. $CRL Shares Sold by Citigroup Inc.

Citigroup Inc. reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 75.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 35,838 shares of the medical research company’s stock after selling 110,759 shares during the quarter. Citigroup Inc. owned about 0.07% of Charles River Laboratories International worth $5,607,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Rothschild Investment LLC raised its position in shares of Charles River Laboratories International by 82.4% during the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after buying an additional 84 shares in the last quarter. Neo Ivy Capital Management bought a new stake in Charles River Laboratories International during the second quarter worth approximately $29,000. Atlantic Union Bankshares Corp bought a new stake in Charles River Laboratories International during the third quarter worth approximately $31,000. Geneos Wealth Management Inc. lifted its position in Charles River Laboratories International by 98.0% in the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after purchasing an additional 145 shares during the period. Finally, Allworth Financial LP boosted its stake in Charles River Laboratories International by 172.7% during the 2nd quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 190 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the topic of a number of research reports. Bank of America raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective on the stock in a research note on Monday, December 15th. Wall Street Zen cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Citigroup raised their price objective on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the company a “buy” rating in a research report on Friday, January 16th. JPMorgan Chase & Co. lifted their price objective on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research note on Monday, December 15th. Finally, Argus set a $200.00 target price on shares of Charles River Laboratories International in a report on Monday, November 17th. Ten equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and a consensus price target of $203.57.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $175.71 on Wednesday. The company has a 50-day moving average of $196.77 and a two-hundred day moving average of $180.59. The stock has a market cap of $8.65 billion, a price-to-earnings ratio of -59.36, a PEG ratio of 3.05 and a beta of 1.64. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $228.88.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The business had revenue of $994.23 million for the quarter, compared to analyst estimates of $986.98 million. During the same quarter in the previous year, the business earned $2.66 earnings per share. The firm’s revenue was down .8% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.